FDA To Revise Warning Label On Bone Drugs
The U.S. Food and Drug Administration is revising the label on bisphosphonate-based osteoporosis drugs to warn consumers that they could raise the risk of a rare type of thigh-bone fracture....To view the full article, register now.
Already a subscriber? Click here to view full article